scholarly journals The Effects From Oral Administration of Recombinant Interferon-alpha on Piglet Daily Care

Author(s):  
Fawen Dai ◽  
Yanting Liu ◽  
Meimei Zhang ◽  
Lin Tao ◽  
Chu Huashuo ◽  
...  

Abstract The administration of interferon has improved the antiviral and immunomodulatory abilities of piglets, which is conductive to conductive to the prevention of potential diseases or delay the appearance of clinical symptoms. This study aimed to evaluate the effects from administration of recombinant interferon-alpha (IFN-α) on the daily care of piglets. The results were compared with compound Chinese herbal, which was proved to improve serum interferon level. Further, the administration routes were compared between oral administration and intramuscular injection. Forty (40) piglets with equal age and weight were randomly divided into four groups: Control group (Group C, without treatment), Group H (treated with compound Chinese herbal), Group K (administered orally with recombinant IFN-α, 1500 IU per day per piglet), and Group J (administered intramuscularly with IFN-α, 4× 106 IU per day per piglet). After the treatment of 15 days, both oral and intramuscular treatment of recombinant IFN-α significantly improved the secretion of IFN-gamma (IFN-γ) (P<0.05), and the effects of intramuscular pathway were faster. In addition, the expression levels of IFN-stimulated genes (MX1 and ISG15) were significantly enhanced (P<0.01), independently of IFN-α treatment time and serum IFN-γ level. Different from other studies, compound Chinese herbal showed weaker effects on interferon stimulation in piglets. The results indicated that oral administration of recombinant IFN-α improved interferon-induced response of piglets at both serum and molecular levels, which may be applied for improving autoimmunity of piglets.

2021 ◽  
Author(s):  
Fawen Dai ◽  
Yanting Liu ◽  
Meimei Zhang ◽  
Lin Tao ◽  
Chu Huashuo ◽  
...  

Abstract The administration of interferon has improved the antiviral and immunomodulatory abilities of piglets, which is conductive to the prevention and control of diseases, such as African swine fever. This study aimed to evaluate the effects from oral administration of interferon-alpha (IFN-α) on the daily care of piglets. The results were compared with compound Chinese herbal, which was proved to improve serum interferon level. Further, the administration routes were compared between oral administration and intramuscular injection. Forty (40) piglets with equal age and weight were randomly divided into four groups: Control group (Group C, without treatment), Group H (treated with compound Chinese herbal), Group K (administered orally with recombinant IFN-α, 1500 IU per day per piglet), and Group J (administered intramuscularly with IFN-α, 4× 106 IU per day per piglet). After the treatment of 15 days, both oral and intramuscular treatment of recombinant IFN-α significantly improved the secretion of IFN-gamma (IFN-γ) (P<0.05), and the effects of intramuscular pathway were faster. In addition, the expression levels of IFN-stimulated genes (MX1 and ISG15) were significantly enhanced (P<0.01), independently of IFN-α treatment time and serum IFN-γ level. Different from other studies, compound Chinese herbal showed weaker effects on interferon stimulation in piglets. The results indicated that oral administration of recombinant IFN-α improved interferon-induced response of piglets at both serum and molecular levels, which may be applied for improving autoimmunity of piglets.


2021 ◽  
pp. 16-25
Author(s):  
A.V. Mordyk ◽  
◽  
O.G. Ivanova ◽  
K.Yu. Samsonov ◽  
S.V. Sitnikova ◽  
...  

Objective. To evaluate the efficacy and safety of human recombinant interferon alpha-2b (VIFERON®) as a part of comprehensive treatment for coronavirus infection COVID-19. Patients and methods. This prospective, comparative, controlled study included 140 patients with COVID-19 randomized in two groups. The experimental group (EG) included 70 patients who received standard therapy plus VIFERON® (one rectal suppository 3,000,000 IU three times a day and gel 36,000 IU/g 5 times a day applied to the nasal mucosa and palatine tonsils for 14 days); the control group (CG) comprised 70 patients who received standard therapy alone. Results. Patients in the EG demonstrated more rapid resolution of main symptoms, such as intoxication, bronchopulmonary and catarrhal manifestations. Normalization of the total score in the EG was observed 7 days earlier than in the CG. In the EG, the proportions of patients who had their D-dimer and CRP levels normalized were 42.7% and 18.7% higher than those in the CG, respectively (р < 0.05). Follow-up computed tomography demonstrated that the proportion of patients with positive dynamics in the EG was 8.1% higher than that among controls, whereas advanced disease with 51%–75% of lung tissue affected was 11.9% less common in participants from the EG than in controls (р = 0.019). We observed no adverse events associated with interferon alpha-2b (VIFERON®) or other medicines included in the treatment scheme. Conclusion. Our findings suggest high efficacy and safety of recombinant interferon alpha-2b (VIFERON®) used in combination with symptomatic agents, antibiotics, anticoagulants, which allows us to recommend this drug for inclusion into standard treatment schemes for COVID-19. Key words: COVID-19, coronavirus infection, human recombinant interferon alpha-2b


1988 ◽  
Vol 85 (2) ◽  
pp. 147-151 ◽  
Author(s):  
Drew J. Winston ◽  
Lawrence J. Eron ◽  
Monto Ho ◽  
George Pazin ◽  
Harold Kessler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document